NCT06328777Phase 2, phase 3Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Study sponsor: Cabaletta Bio

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-07Estimated
Enrollment · participants37Estimated
Source updated2026-10-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate incidence of adverse events. After: Measure: Phase 1/2: To evaluate incidence of adverse events Measure: Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects.

Planned enrollment increased by 25 participants

Before: 12 participants (planned). After: 37 participants (planned).

Phase changed

Before: PHASE1, PHASE2. After: PHASE2, PHASE3.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview